Home / Latest Reports / Spinal Muscular Atrophy Sma Treatment Market

Spinal Muscular Atrophy (SMA) Treatment Market By Type and Treatment - Global Industry Analysis & Forecast to 2027

Published On : November 2018 Pages : 170 Category: Pharma & Healthcare Report Code : HC121944

Request Sample Inquiry Before Buying Request for Customization Check Discount

Spinal Muscular Atrophy (SMA) Treatment Market By Type (Type I, Type II, Type III, Type IV) Treatment (Drugs, Gene replacement surgery or therapy) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Spinal Muscular Atrophy (SMA) Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Spinal solid atrophy (SMA) is associated to a group of acquired ailments that influences the working of muscles as a result of deterioration. It commonly results in weakness, and may even result in death. SMA influences the motor neurons present in the spinal cord and brain. These engine neurons are in charge of the exchange of electric and compound signs to and from the voluntary muscles of the body, empowering different physical exercises, for example, crawling, walking, swallowing, and others.

Drivers and Restraints

One of the main aspects driving the worldwide SMA treatment market is an expansion in the commonness of SMA. Also, factors, for example, progressions in technology, increasing awareness, supportive government activities, and enhancement in the repayment situation are boosting the worldwide SMA treatment market. Nonetheless, the market will confront obstacles as the increasing expenses of treatment and absence of experienced experts. Also, a low selection rate of SMA treatment choices is limiting the market.

Regional Insights

North America drove the market in 2022. This development was because of most extreme income produced by U.S. market. Since Spinraza was affirmed in the nation in December 2017.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Isis Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Regeneron Pharmaceuticals, Inc
  • Pfizer, Inc
  • Biogen Idec
  • F. Hoffmann-La Roche AG

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Spinal Muscular Atrophy (SMA) Treatment Market, By Type, Estimates and Forecast, 2017-2027 ($Million)

·         Type I

·         Type II

·         Type III

·         Type IV

·         Spinal Muscular Atrophy (SMA) Treatment Market, By End User, Estimates and Forecast, 2017-2027 ($Million)

·         Drugs

·         Gene replacement surgery or therapy

·         Spinal Muscular Atrophy (SMA) Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

·         North America

§  North America Spinal Muscular Atrophy (SMA) Treatment Market, By Country

o    U.S. Spinal Muscular Atrophy (SMA) Treatment Market

o    Canada Spinal Muscular Atrophy (SMA) Treatment Market

o    Mexico Spinal Muscular Atrophy (SMA) Treatment Market

·         Europe

§  Europe Spinal Muscular Atrophy (SMA) Treatment Market, By Country

o    Germany Spinal Muscular Atrophy (SMA) Treatment Market

o    UK Spinal Muscular Atrophy (SMA) Treatment Market

o    France Spinal Muscular Atrophy (SMA) Treatment Market

o    Russia Spinal Muscular Atrophy (SMA) Treatment Market

o    Italy Spinal Muscular Atrophy (SMA) Treatment Market

o    Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Market

·         Asia-Pacific

§  Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market, By Country

o    China Spinal Muscular Atrophy (SMA) Treatment Market

o    Japan Spinal Muscular Atrophy (SMA) Treatment Market

o    South Korea Spinal Muscular Atrophy (SMA) Treatment Market

o    India Spinal Muscular Atrophy (SMA) Treatment Market

o    Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market

o    Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market

·         South America

§  South America Spinal Muscular Atrophy (SMA) Treatment Market

o    Brazil Spinal Muscular Atrophy (SMA) Treatment Market

o    Argentina Spinal Muscular Atrophy (SMA) Treatment Market

o    Columbia Spinal Muscular Atrophy (SMA) Treatment Market

o    Rest of South America Spinal Muscular Atrophy (SMA) Treatment Market

·         Middle East and Africa

§  Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Market

o    Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Market

o    UAE Spinal Muscular Atrophy (SMA) Treatment Market

o    Egypt Spinal Muscular Atrophy (SMA) Treatment Market

o    Nigeria Spinal Muscular Atrophy (SMA) Treatment Market

o    South Africa Spinal Muscular Atrophy (SMA) Treatment Market

o    Rest of MEA Spinal Muscular Atrophy (SMA) Treatment Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Spinal Muscular Atrophy (SMA) Treatment Market, By Type

5.1.     Introduction

5.2.     Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Market Share by Type  (2017-2027)

5.2.1.  Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Revenue Share by Type  (2017-2027)

5.3.     Type I

5.3.1.  Global Type I  Revenue and Growth Rate (2017-2027)

5.4.     Type II

5.4.1.  Global Type II Revenue and Growth Rate (2017-2027)

5.5.     Type III

5.5.1.  Global Type III Revenue and Growth Rate (2017-2027)

5.6.     Type IV

5.6.1.  Global Type IV  Revenue and Growth Rate (2017-2027)

6.       Spinal Muscular Atrophy (SMA) Treatment Market, By Treatment

6.1.     Introduction

6.2.     Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Market Share by Treatment (2017-2027)

6.2.1.  Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Revenue Share by Treatment (2017-2027)

6.3.     Drugs

6.3.1.  Global Drugs Revenue and Growth Rate (2017-2027)

6.4.     Gene replacement surgery or therapy

6.4.1.  Global Gene replacement surgery or therapy Revenue and Growth Rate (2017-2027)

7.       Spinal Muscular Atrophy (SMA) Treatment Market, By Region

7.1.     Introduction

7.2.     Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Market Share by Regions

7.2.1.  Global Spinal Muscular Atrophy (SMA) Treatment Revenue by Regions (2017-2027)

7.3.     North America Spinal Muscular Atrophy (SMA) Treatment by Countries

7.3.1.  North America Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2027)

7.3.2.  North America Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2027)

7.3.3.  United States

7.3.3.1.  United States Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.4.  Canada

7.3.4.1.  Canada Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.5.  Mexico

7.3.5.1.  Mexico Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.     Europe Spinal Muscular Atrophy (SMA) Treatment by Countries

7.4.1.  Europe Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2027)

7.4.2.  Europe Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2027)

7.4.3.  Germany

7.4.3.1.  Germany Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.4.  France

7.4.4.1.  France Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.5.  UK

7.4.5.1.  UK Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.6.  Russia

7.4.6.1.  Russia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.7.  Italy

7.4.7.1.  Italy Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.     Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment by Countries

7.5.1.  Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2027)

7.5.2.  Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2027)

7.5.3.  China

7.5.3.1.  China Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.4.  Japan

7.5.4.1.  Japan Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.5.  Korea

7.5.5.1.  Korea Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.6.  India

7.5.6.1.  India Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.     South America Spinal Muscular Atrophy (SMA) Treatment by Countries

7.6.1.  South America Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2027)

7.6.2.  South America Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2027)

7.6.3.  Brazil

7.6.3.1.  Brazil Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.4.  Argentina

7.6.4.1.  Argentina Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.5.  Columbia

7.6.5.1.  Columbia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.     Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment by Countries

7.7.1.  Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2027)

7.7.2.  Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2027)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.5.  Egypt

7.7.5.1.  Egypt Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.7.  South Africa

7.7.7.1.  South Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.8.  Turkey

7.7.8.1.  Turkey Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

8.       Company Profiles

8.1.     Isis Pharmaceuticals, Inc.

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.   Revenue and Market Share

8.2.     Boehringer Ingelheim GmbH

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.   Revenue and Market Share

8.3.     Regeneron Pharmaceuticals, Inc

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.   Revenue and Market Share

8.4.     Pfizer, Inc

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.   Revenue and Market Share

8.5.     Biogen Idec

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.   Revenue and Market Share

8.6.     F. Hoffmann-La Roche AG

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.   Revenue and Market Share

9.       Global Spinal Muscular Atrophy (SMA) Treatment Market Competition, by Manufacturer

9.1.     Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Market Share by Manufacturer (2017-2017)

9.2.     Global Spinal Muscular Atrophy (SMA) Treatment Price By Region (2017-2017)

9.3.     Top 5 Spinal Muscular Atrophy (SMA) Treatment Manufacturer Market Share

9.4.     Market Competition Trend

10.    Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.1. Global Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

10.2. Spinal Muscular Atrophy (SMA) Treatment Market Forecast by Regions (2017-2027)

10.2.1.      North America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.1.1. United States Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.1.2. Canada Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.1.3. Mexico Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.      Europe Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.1. Germany Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.2. France Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.3. UK Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.4. Russia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.5. Italy Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.2.6. Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.      Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.1. China Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.2. Japan Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.3. Korea Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.4. India Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.5. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.3.6. Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.4.      South America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.4.1. Brazil Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.4.2. Argentina Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.4.3. Columbia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.4.4. Rest of South America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.      Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.1. Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.2. United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.3. Egypt Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.4. Nigeria Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.5. South Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.6. Turkey Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.2.5.7. Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2017-2027)

10.3. Spinal Muscular Atrophy (SMA) Treatment Market Forecast by Type  (2017-2027)

10.3.1.      Spinal Muscular Atrophy (SMA) Treatment Forecast by Type  (2017-2027)

10.3.2.      Spinal Muscular Atrophy (SMA) Treatment Market Share Forecast by Type  (2017-2027)

10.4. Spinal Muscular Atrophy (SMA) Treatment Market Forecast by Treatment (2017-2027)

10.4.1.      Spinal Muscular Atrophy (SMA) Treatment Forecast by Treatment (2017-2027)

10.4.2.      Spinal Muscular Atrophy (SMA) Treatment Market Share Forecast by Treatment (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Revenue Share by Type (2017-2018)
Figure Global Type I Revenue and Growth Rate (2017-2018)
Figure Global Type II Revenue and Growth Rate (2017-2018)
Figure Global Type III Revenue and Growth Rate (2017-2018)
Figure Global Type IV Revenue and Growth Rate (2017-2018)
Table Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Drugs Revenue and Growth Rate (2017-2018)
Figure Global Gene replacement surgery or therapy Revenue and Growth Rate (2017-2018)
Table Global Spinal Muscular Atrophy (SMA) Treatment Revenue by Regions (2017-2018)
Figure North America Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure North America Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2018)
Figure North America Spinal Muscular Atrophy (SMA) Treatment by Countries (2017-2018)
Figure North America Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure United States Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure United States Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Canada Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Europe Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2018)
Figure Europe Spinal Muscular Atrophy (SMA) Treatment by Countries (2017-2018)
Figure Europe Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Germany Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Germany Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure France Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure UK Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Russia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Italy Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment by Countries (2017-2018)
Figure Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure China Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure China Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Japan Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Korea Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure India Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure South America Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2018)
Figure South America Spinal Muscular Atrophy (SMA) Treatment by Countries (2017-2018)
Figure South America Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Columbia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Rest of South America Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment by Countries (2017-2018)
Figure Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Table Isis Pharmaceuticals, Inc. Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Boehringer Ingelheim GmbH Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Regeneron Pharmaceuticals, Inc Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer, Inc Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann-La Roche AG Spinal Muscular Atrophy (SMA) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Manufacturer
Figure Global Spinal Muscular Atrophy (SMA) Treatment Revenue and Market Share by Manufacturer
Table Global Spinal Muscular Atrophy (SMA) Treatment Price by Region (2017-2017)
Figure Top 5 Spinal Muscular Atrophy (SMA) Treatment Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Spinal Muscular Atrophy (SMA) Treatment Revenue (Millions USD) and Growth Rate (2018-2025)
Table Spinal Muscular Atrophy (SMA) Treatment Market Forecast by Regions (2018-2025)
Figure North America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure United States Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Canada Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Europe Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Germany Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure France Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure UK Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Russia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Italy Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Rest of Europe Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure China Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Japan Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Korea Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure India Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure South America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Columbia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Rest of South America Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Spinal Muscular Atrophy (SMA) Treatment Market Forecast (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Forecast by Type (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Market Share Forecast by Type (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Forecast by Type (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Forecast by Treatment (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Market Share Forecast by Treatment (2018-2025)
Figure Global Spinal Muscular Atrophy (SMA) Treatment Forecast by Treatment (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*